Stocks and Investing
Stocks and Investing
Fri, July 15, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (TSVT) at Buy with Decreased Target to $28 on, Jul 15th, 2022
Matthew Harrison of Morgan Stanley, Maintained "2seventy bio, Inc." (TSVT) at Buy with Decreased Target from $31 to $28 on, Jul 15th, 2022.
Matthew has made no other calls on TSVT in the last 4 months.
There is 1 other peer that has a rating on TSVT. Out of the 1 peers that are also analyzing TSVT, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Salveen Richter of "Goldman Sachs" Initiated at Strong Buy and Held Target at $26 on, Monday, May 2nd, 2022
Contributing Sources